Michael Lahn
Dr Michael Lahn is the Chief Medical Officer of iOnctura. He joined iOnctura as Chief Medical Officer in 2019 after 20 years of industry experience at Eli Lilly and Company, AstraZeneca and Incyte Corporation. In his career, Lahn contributed to the development of several new molecular entities, such as small molecule inhibitors (including the ALK5 inhibitor galunisertib and the registration of osimertinib in NSCLC), large molecules, antisense oligonucleotides and vaccines. He is passionate about developing novel therapies in cancer and mentoring colleagues in clinical drug development.